Figure 2.
Validation of the FCGR2B prognostic effect by NanoString and prognostic effect of FcγRIIB protein expression measured by IHC in the Arthur cohort. (A) Correlation between FCGR2B expression measured by NanoString and RNA-Seq. (B) Kaplan-Meier curve for PFS based on FCGR2B expression measured by NanoString. Cox regression results based on FCGR2B expression dichotomized by median. (C) Correlation of FCGR2B expression by RNA-Seq with FcγRIIB protein expression. (D) Kaplan-Meier curves for PFS according to high, low and negative FcγRIIB tumor expression. (E-F) according to stratification by COO. Tumor membrane staining for FcgRIIB was defined as high (at least medium intensity staining with ≥50% positive cells); low (membrane positive, low intensity staining or <50% positive cells) or negative (cytoplasmic staining or negative membrane staining).

Validation of the FCGR2B prognostic effect by NanoString and prognostic effect of FcγRIIB protein expression measured by IHC in the Arthur cohort. (A) Correlation between FCGR2B expression measured by NanoString and RNA-Seq. (B) Kaplan-Meier curve for PFS based on FCGR2B expression measured by NanoString. Cox regression results based on FCGR2B expression dichotomized by median. (C) Correlation of FCGR2B expression by RNA-Seq with FcγRIIB protein expression. (D) Kaplan-Meier curves for PFS according to high, low and negative FcγRIIB tumor expression. (E-F) according to stratification by COO. Tumor membrane staining for FcgRIIB was defined as high (at least medium intensity staining with ≥50% positive cells); low (membrane positive, low intensity staining or <50% positive cells) or negative (cytoplasmic staining or negative membrane staining).

Close Modal

or Create an Account

Close Modal
Close Modal